CY1114823T1 - Φαινυλ-αλκυλ πιπεραζινες οι οποιες διαθετουν μια ρυθμιστικη δραστηριοτητα του τνf - Google Patents

Φαινυλ-αλκυλ πιπεραζινες οι οποιες διαθετουν μια ρυθμιστικη δραστηριοτητα του τνf

Info

Publication number
CY1114823T1
CY1114823T1 CY20131101052T CY131101052T CY1114823T1 CY 1114823 T1 CY1114823 T1 CY 1114823T1 CY 20131101052 T CY20131101052 T CY 20131101052T CY 131101052 T CY131101052 T CY 131101052T CY 1114823 T1 CY1114823 T1 CY 1114823T1
Authority
CY
Cyprus
Prior art keywords
tnf
finyl
regulatory activity
alkyl piperazines
piperazines
Prior art date
Application number
CY20131101052T
Other languages
English (en)
Inventor
Marco Baroni
Olaf Ritzeler
Marco Zanchet
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0803337A external-priority patent/FR2932480B1/fr
Priority claimed from FR0807361A external-priority patent/FR2940288B1/fr
Application filed by Sanofi filed Critical Sanofi
Publication of CY1114823T1 publication Critical patent/CY1114823T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)

Abstract

Η παρούσα εφεύρεση αφορά νέες φαινυλ-αλκυλ-πιπεραζίνες οι οποίες διαθέτουν μια ρυθμιστική δραστηριότητα του TNF, τις φαρμακευτικές συνθέσεις οι οποίες τις περιέχουν και μια διαδικασία για την παρασκευή τους.
CY20131101052T 2008-06-16 2013-11-25 Φαινυλ-αλκυλ πιπεραζινες οι οποιες διαθετουν μια ρυθμιστικη δραστηριοτητα του τνf CY1114823T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0803337A FR2932480B1 (fr) 2008-06-16 2008-06-16 Phenyl-alkyl-piperazines ayant une activite modulatrice du tnf
FR0807361A FR2940288B1 (fr) 2008-12-23 2008-12-23 Phenyl-alkyl-piperazines ayant une activite modulatrice du tnf
EP09766076.5A EP2313384B1 (fr) 2008-06-16 2009-06-16 Phenyl-alkyl piperazines ayant une activite modulatrice du tnf

Publications (1)

Publication Number Publication Date
CY1114823T1 true CY1114823T1 (el) 2016-12-14

Family

ID=41278405

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101052T CY1114823T1 (el) 2008-06-16 2013-11-25 Φαινυλ-αλκυλ πιπεραζινες οι οποιες διαθετουν μια ρυθμιστικη δραστηριοτητα του τνf

Country Status (24)

Country Link
US (1) US8153637B2 (el)
EP (1) EP2313384B1 (el)
JP (1) JP5536050B2 (el)
KR (1) KR20110028452A (el)
CN (2) CN102123995A (el)
AR (1) AR072120A1 (el)
AU (1) AU2009261783B2 (el)
BR (1) BRPI0914815A2 (el)
CA (1) CA2727911C (el)
CY (1) CY1114823T1 (el)
DK (1) DK2313384T3 (el)
ES (1) ES2433218T3 (el)
HR (1) HRP20131183T1 (el)
IL (1) IL209944A (el)
JO (1) JO2857B1 (el)
MX (1) MX2010013947A (el)
MY (1) MY153051A (el)
PL (1) PL2313384T3 (el)
PT (1) PT2313384E (el)
RU (1) RU2512567C2 (el)
SI (1) SI2313384T1 (el)
TW (1) TW201002687A (el)
UY (1) UY31902A (el)
WO (1) WO2009153514A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6173693B2 (ja) * 2010-02-24 2017-08-02 リサーチ・トライアングル・インスティチュート アリールピペラジンオピオイド受容体アンタゴニスト
CN105061352A (zh) * 2015-07-29 2015-11-18 广州市广金投资管理有限公司 芳基哌嗪衍生物ⅲ及其盐、制备方法和用途
KR20210116517A (ko) * 2019-01-11 2021-09-27 에일러 파마슈티컬스 아이엔씨. 케타민 파모에이트 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171251A (en) * 1967-07-05 1969-11-19 British Drug Houses Ltd Preparation of Piperazine Derivatives
DE19637237A1 (de) * 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
NZ504465A (en) * 1997-10-14 2001-11-30 Welfide Corp 1-Phenylacylamino substituted piperazine derivatives which are 4-substituted by a heteroaryl group
DE19801597C2 (de) * 1998-01-17 2001-05-03 Aventis Res & Tech Gmbh & Co Basenkatalysierte Synthese von 1-Aryl-4-(arylethyl)piperazinen aus aromatischen Olefinen und 1-Arylpiperazinen
JP2001072660A (ja) * 1999-09-08 2001-03-21 Welfide Corp ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤
WO2004060308A2 (en) * 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
AU2008255885A1 (en) * 2007-05-24 2008-12-04 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
FR2932480B1 (fr) * 2008-06-16 2010-11-12 Sanofi Aventis Phenyl-alkyl-piperazines ayant une activite modulatrice du tnf

Also Published As

Publication number Publication date
IL209944A (en) 2014-01-30
EP2313384A1 (fr) 2011-04-27
PL2313384T3 (pl) 2014-03-31
SI2313384T1 (sl) 2013-12-31
HRP20131183T1 (hr) 2014-01-17
CN102123995A (zh) 2011-07-13
TW201002687A (en) 2010-01-16
MY153051A (en) 2014-12-31
AR072120A1 (es) 2010-08-04
AU2009261783B2 (en) 2014-08-07
WO2009153514A1 (fr) 2009-12-23
RU2512567C2 (ru) 2014-04-10
JO2857B1 (en) 2015-03-15
PT2313384E (pt) 2013-12-09
ES2433218T3 (es) 2013-12-10
RU2011101396A (ru) 2012-07-27
JP2011524409A (ja) 2011-09-01
JP5536050B2 (ja) 2014-07-02
UY31902A (es) 2010-01-29
KR20110028452A (ko) 2011-03-18
US8153637B2 (en) 2012-04-10
CA2727911C (fr) 2017-01-03
AU2009261783A1 (en) 2009-12-23
IL209944A0 (en) 2011-02-28
EP2313384B1 (fr) 2013-09-18
CN105198803A (zh) 2015-12-30
MX2010013947A (es) 2011-02-23
BRPI0914815A2 (pt) 2015-10-27
DK2313384T3 (da) 2014-01-13
CA2727911A1 (fr) 2009-12-23
US20110144120A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CY1121572T1 (el) Σκευασμα δισκιου του ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου για χρηση στη θεραπεια κυστικης ινωσης
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
CY1119245T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1118682T1 (el) Ενωσεις πυραζολης ως αναστολεις του υποδοχεα σιγμα
CY1117886T1 (el) Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
EA201170772A1 (ru) Органические соединения
CY1118231T1 (el) Συνθεση λιποσωματος
CY1110812T1 (el) Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA201300388A1 (ru) Соединения замещенного бензамида
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
CY1111367T1 (el) Νεα παραγωγα της διοσμετινης, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола